Functional Outcomes and Quality of Life in High-risk Prostate Cancer Patients Treated by Robot-assisted Radical Prostatectomy with or Without Adjuvant Treatments

Wout Devlies; Geert Silversmit; Filip Ameye; Peter Dekuyper; Thierry Quackels; Thierry Roumeguère; Ben Van Cleynenbreugel; Nancy Van Damme; Frank Claessens; Wouter Everaerts; Steven Joniau; Be-RALP: the Belgian RALP Consortium

doi:10.1016/j.euo.2024.04.018

Functional Outcomes and Quality of Life in High-risk Prostate Cancer Patients Treated by Robot-assisted Radical Prostatectomy with or Without Adjuvant Treatments

Eur Urol Oncol. 2024 May 15:S2588-9311(24)00107-X. doi: 10.1016/j.euo.2024.04.018. Online ahead of print.

Affiliations

¹ Department of Urology, KU Leuven, Leuven, Belgium; Department of Development and Regeneration, KU Leuven, Leuven, Belgium. Electronic address: wout.devlies@kuleuven.be.
² Belgian Cancer Registry, Brussels, Belgium.
³ Department of Urology, Maria Middelares Hospital, Ghent, Belgium.
⁴ Department of Urology, Université Libre De Bruxelles, Brussels, Belgium.
⁵ Department of Urology, KU Leuven, Leuven, Belgium.
⁶ Laboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium.
⁷ Department of Urology, KU Leuven, Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, Belgium.
⁸ Department of Urology, KU Leuven, Leuven, Belgium; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

PMID: 38755093
DOI: 10.1016/j.euo.2024.04.018

Abstract

Background: Robot-assisted laparoscopic prostatectomy (RALP) is used frequently to treat prostate cancer; yet, prospective data on the quality of life and functional outcomes are lacking.

Objective: To assess the quality of life and functional outcomes after radical prostatectomy in different risk groups with or without adjuvant treatments.

Design, setting, and participants: The Be-RALP database is a prospective multicentre database that covers 9235 RALP cases from 2009 until 2016. Of these 9235 patients, 2336 high-risk prostate cancer patients were matched with low/intermediate-risk prostate cancer patients.

Intervention: Patients were treated with RALP only or followed by radiotherapy and/or hormone treatment.

Outcome measurements and statistical analysis: We used a mixed-model analysis to longitudinally analyse quality of life, urinary function, and erectile function between risk groups with or without additional treatments.

Results and limitations: Risk group was not significant in predicting quality of life, erectile function, or urinary function after RALP. Postoperative treatment (hormone and/or radiotherapy treatment) was significant in predicting International Index of Erectile Function (IIEF-5), sexual activity, and sexual functioning.

Conclusions: Risk group was not linked with clinically relevant declines in functional outcomes after RALP. The observed functional outcomes and quality of life are in favour of considering RALP for high-risk prostate cancer. Postoperative treatment resulted in lower erectile function measures without clinically relevant changes in quality of life and urinary functions. Hormone therapy seems to have the most prominent negative effects on these outcomes.

Patient summary: This study investigated the quality of life, and urinary and erectile function in patients with aggressive and less aggressive prostate cancer after surgery only or in combination with hormones or radiation. We found that quality of life recovers completely, while erectile and urinary function recovers only partially after surgery. Aggressiveness of the disease had a minimal effect on the outcomes; yet, postoperative treatments lowered erectile function further.

Keywords: Continence; Erectile dysfunction; Functional outcomes; High-risk prostate cancer; Quality of life; Radical prostatectomy; Robot-assisted radical prostatectomy; Sexual health; Urinary symptoms.